Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection

Antiviral Research

Volumn 89, Issue 3, 2011, Pages 232-237

  Ren, Shan ^a   Yu, Haibin ^a   Zhang, Hongwei ^a   Liu, Ying ^b   Huang, Yanxiang ^a   Ma, Lina ^a   Wei, Lai ^c   Wu, Hao ^a   Chen, Xinyue ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

2',5' Oligoadenylate synthetase(OAS); Haplotype; HBsAg seroconversion; Hepatitis B virus (HBV); Interferon ; Single nucleotide polymorphism (SNP)

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALPHA INTERFERON;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG RESPONSE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

2',5'-OLIGOADENYLATE SYNTHETASE; GENE FREQUENCY; HAPLOTYPES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 79951584831     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.01.006     Document Type: Article

References (24)

1. Ahmadi K.R., Weale M.E., Xue Z.Y., Soranzo N., Yamall D.P., Briley J.D., Maruyama Y., Kobayashi M., Wood N.W., Spurr N.K., Burns D.K., Roses a.d., Saunders A.M., Goldstein D.B. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat. Genet. 2005, 37:84-89.
2. Akman S.A., Okcu S.C., Halicioĝlu O., Sutcuoglu S., Anil M., Kizilgunesler A., Bakiler A.R. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr. Int. 2007, 49:848-852.
3. Bonnevie-Nielsen V., Field L.L., Lu S., Zheng D.J., Li M., Martensen P.M., Nielsen T.B., Beck-Nielsen H., Lau Y.L., Pociot F. Variation in antiviral 2',5'-oligoadenylate synthetase (2',5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am. J. Hum. Genet. 2005, 76:623-633.
4. Cao Z., Chen X., Yu H., Jin Y., Ren S., Huang Y., Sun G., Ma B. Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40kD] plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/seroconversion. AASLD 2010, (Abstract).
5. Cao Z., Chen X., Yu H., Jin Y., Ren S., Huang Y., Sun G., Ma B. Interferon/peginterferon alpha plus nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B-very potent HBsAg response. AASLD 2010, (Abstract).
6. Chan H.L., Tse A.M., Zhang M.D., Wong V.W., Chim A.M., Hui A.Y., Sung J.J. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment. Pharmacol. Ther. 2006, 23:1703-1711.
7. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., Linuma K., Mushahwar I.K. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J. Virol. Methods 2004, 115:217-222.
8. EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association for the Study of the Liver. J. Hepatol. 2009, 50:227-242.
9. García-Sastre A., Biron C.A. Type 1 interferons and the virus host relationship: a lesson in détente. Science 2006, 312:879-882.
10. Hovanessian A.G., Justesen J. The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie 2007, 89:779-788.
11. King J.K., Yeh S.H., Lin M.W., Liu C.J., Lai M.Y., Kao J.H., Chen D.S., Chen P.J. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. J. Hepatol. 2002, 36:1416-1424.
12. Knapp S., Yee L.J., Frodsham A.J., Henning B.J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M., Thomas H.C., Hill A.V., Thursz M.R. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003, 4:411-419.
13. Kong X.F., Zhang X.X., Gong Q.M., Gao J., Zhang S.Y., Wang L., Xu J., Han Y., Jin G.D., Jiang J.H., Zhang D.H., Lu Z.M. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment. J. Interferon Cytokine Res. 2007, 27:809-818.
14. Liu J., Yang H.-I., Lee M.-H., Lu S.-N., Jen C.-L., Wang L.-Y., You S.-L., IIoeje U.H., Chen C.-J. Incidence and determinants of spontaneous hepatititis B surface antigen seroclearance: a community-based long-term follow-up study. J. Hepatol. 2010, 52:S281.
15. Ovsyannikova I.G., Ryan J.E., Vierkant R.A., O'Byrne M.M., Pankratz V.S., Jacobson R.M., Poland G.A. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine 2009, 27:3359-3366.
16. Ozaras R., Tabak F., Tahan V., Ozturk R., Akin H., Mert A., Senturk H. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig. Dis. Sci. 2008, 53:2995-2998.
17. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89:1-47.
18. Rodella A., Galli C., Terlenghi L., Perandin F., Bonfanti C., Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J. Clin. Virol. 2006, 37:206-212.
19. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008, 8:559-568.
20. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15:97-98.
21. Su X., Yee L.J., Im K.A., Rhodes S.L., Tang Y.M., Tong X., Howell C., Ramcharran D., Rosen H.R., Taylor M.W., Liang T.J., Yang H. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J. Hepatol. 2008, 49:184-191. Virahep-C Study Group.
22. Suzuki F., Arase Y., Suzuki Y., Tsubota A., Akuta N., Hosaka T., Someya T., Kobayashi M., Saitoh S., Ikeda K., Kobayashi M., Matsuda M., Takagi K., Satoh J., Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepatol. 2004, 11:271-276.
23. Wu X., Zhu X., Zhu S., Li J., Ma J., Li Z., Li H., Liu Y. A pharmacogenentic study of polymorphisms in interferon pathway genes and response to interferon-α treatment in chronic hepatitis B patients. Antiviral Res. 2009, 83:252-256.
24. Yakub I., Lillibridge K.M., Moran A., Gonzalez O.Y., Belmont J., Gibbs R.A., Tweardy D.J. Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L in patients hospitalized with West Nile virus infection. J. Infect. Dis. 2005, 192:1741-1748.